Dr. Hawkins is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
86 Jonathan Lucas Street
HO321S
Charleston, SC 29425Phone+1 843-876-4420- Is this information wrong?
Summary
- Dr. William Hawkins is a surgical oncologist in Charleston, SC. He serves as the Deputy Director of the Hollings Cancer Center and focuses his leadership efforts on growth of translational science. He received his medical degree from Stony Brook University School of Medicine and has been in practice 20 years. Clinically he specializes in hepatobiliary surgery, pancreas, and surgical oncology (other than breast) and is experienced in cholangiocarcinoma, minimally invasive surgery, surgical oncology, pancreatectomy, and adenocarcinoma.
Education & Training
- Memorial Sloan Kettering Cancer CenterFellowship, Complex General Surgical Oncology, 2002 - 2004
- Massachusetts General HospitalResidency, Surgery, 2000 - 2002
- Memorial Sloan Kettering Cancer CenterSurgical Research Fellow, 1998 - 2000
- Stony Brook University Health Sciences Center School of MedicineClass of 1995
- State University of New York at Stony BrookBS, Biology, Magna Cum Laude, 1987 - 1991
Certifications & Licensure
- IL State Medical License 2021 - 2026
- SC State Medical License 2023 - 2025
- MO State Medical License 2004 - 2024
- NY State Medical License 1998 - 2005
- American Board of Surgery Surgery
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR, Allscripts, 2012
- Light up the night with hope award PanCAN, 2008
- Mentored Research Scholar American Cancer Society, 2008
- Join now to see all
Clinical Trials
- Registry Study - Whipple at the Splenic Artery Start of enrollment: 2010 Sep 20
- Reinforced Staple Line on Leak Rate in Distal Pancreatectomy Start of enrollment: 2007 Jun 01
- FOLFIRINOX Plus PF-04136309 in Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma Start of enrollment: 2012 Apr 01
- Join now to see all
Publications & Presentations
PubMed
- The novel drug candidate S2/IAPinh improves survival in models of pancreatic and ovarian cancer.Takaomi Hagi, Suwanna Vangveravong, Rony Takchi, Qingqing Gong, S Peter Goedegebuure, Herve Tiriac, Brian A Van Tine, Matthew A Powell, Dirk Spitzer, William G Hawkins> ;Scientific Reports. 2024 Mar 16
- ASO Author Reflections: A Role for Extended VTE Prophylaxis After Neoadjuvant Therapy and Distal Pancreatectomy for Pancreatic Adenocarcinoma.Keenan J Robbins, William G Hawkins> ;Annals of Surgical Oncology. 2024 May 1
- sc2MeNetDrug: A computational tool to uncover inter-cell signaling targets and identify relevant drugs based on single cell RNA-seq data.Feng, J., Goedegebuure, S., Zeng, A., Bi, Y., Wang, T., Payne, P., Ding, L., DeNardo, D., Hawkins, W., Fields, R., Li, F.> ;Plos Computational Biology. 2024 Jan 1
- Join now to see all
Journal Articles
- Post-Discharge Phone Call Intervention After PancreaticoduodenectomyDarren R Cullinan, Chet Hammill, Ryan C Fields, Steven M Strasberg, William G Hawkins, Journal of The American College of Surgeons
- Intensity Modulated Radiation Therapy and Surgery for Management of Retroperitoneal Sarcomas: A Single-Institution ExperienceTodd DeWees, Imran Zoberi, Jeffrey Olsen, Jeff Michalski, William Hawkins, BioMed Central
- Variations in Definition and Method of Retrieval of Complications Influence Outcomes Statistics after Pancreatoduodenectomy: Comparison of NSQIP with Non-NSQIP MethodsSanford DE, Woolsey CA, Hall BL, Linehan DC, Hawkins WG, Fields RC, Strasberg SM, J Am Coll Surg, 9/1/2014
- Join now to see all
Books/Book Chapters
Authored Content
- Post-Discharge Phone Call Intervention After PancreaticoduodenectomyOctober 2018
Press Mentions
- Immune-Boosting Compound Makes Immunotherapy Effective Against Pancreatic CancerJuly 17th, 2019
- Immune-Boosting Compound Makes Immunotherapy Effective Against Pancreatic CancerJuly 3rd, 2019
- $10.4 Million Awarded for Pancreatic Cancer ResearchAugust 15th, 2016
- Join now to see all
Grant Support
- On The Trail To Pancreas Cancer-Selective Tumor Cell Death (APOPTOSIS)National Cancer Institute2010–2011
- Small Fish To Evaluate Toxic ChemicalsNational Institute Of Environmental Health Sciences1994
Professional Memberships
- Member
Hospital Affiliations
- Siteman Cancer CenterSaint Louis, Missouri
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: